Long-form editorial reporting on the European peptide industry — supply chains, clinical-trial design, regulatory capture, and the gap between marketing claims and the underlying science.
What we are building:
- Multi-month investigative pieces, each anchored to primary sources and verified against the underlying literature before publication.
- Document libraries: leaked memos, FOI returns, FDA 483 letters, EMA assessment reports — annotated and searchable.
- Methodology disclosures: every investigation publishes its own data, code and source list under CC-BY.
Standards
Investigations follow the same evidence-grading discipline as the encyclopedia. Claims are anchored to primary sources; absence of evidence is reported as such; no piece runs without two independent reviewers signing off on factual accuracy.
Timeline
First investigation ships Q4 2026 once the encyclopedia and brand docket are mature enough to support cross-reference. Sign up for press notifications at press@peptidepedia.nl.